Navigation Links
Novexel to be Acquired by AstraZeneca
Date:12/23/2009

PARIS, December 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing. The transaction is expected to close in the first quarter of 2010, subject to certain customary conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.

Under the terms of the agreement, AstraZeneca will acquire 100 percent of Novexel's shares for $350 million in cash payable upon completion and will pay up to an additional $75 million to Novexel shareholders if specified development milestones are reached. AstraZeneca will also transfer to Novexel shareholders an amount equivalent to the cash balance of Novexel at closing. The cash balance of Novexel at closing is expected to be approximately $80 million. This transaction will provide AstraZeneca with an attractive portfolio of clinical and preclinical compounds which are designed to address infections caused by drug-resistant bacteria in the hospital.

    Novexel's clinical development pipeline includes:

    - NXL104, a novel beta-lactamase inhibitor. NXL104 in
      combination with the cephalosporin antibiotic ceftazidime (CAZ-104) is
      currently in two Phase II clinical trials in patients with complicated
      intra-abdominal infections (cIAIs) and patients with complicated
      urinary tract infections (cUTIs). Under an agreement concluded in
      January 2008, Novexel granted Forest Laboratories the rights to develop
      NXL104 in combination with ceftaroline (CEF-104) in North Ame
'/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
6. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... Toronto (PRWEB) September 23, 2014 ... the Canadian specialty market, is now providing U.S. ... its new 160,000-square-foot distribution center coupled with its ... Canadian healthcare industry has historically been difficult for ... to government regulation complexities. As a result of ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 The print ... of the Metro, with a circulation of approximately 327,720 ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... features an exclusive interview with Michael Landsberg, host of ...
(Date:9/23/2014)... 2014 Antibiotics revolutionized health care in the ... killed thousands of people. But bacteria are also ... bacteria are popping up more frequently. This week,s ... of new antibiotics and discusses the prospects for ... Why should you finish your pills if you ...
(Date:9/23/2014)... to what is often assumed about single parents, particularly ... The Kinsey Institute has found that single parents of ... as often as singles without children -- and more ... study, "Dating and Sexual Behavior Among Single Parents of ... in the Journal of Sex Research prior ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 On September 23, ... Keith Simmons for an episode. Simmons is the founder of ... believed the audience would like to know. At the start ... the idea to start this magazine?” Simmons replied by saying, ... sales person. In 2005, I quit that and decided to ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... Society for Gastrointestinal Endoscopy (ASGE) and the American Society ... new white paper on the potential role of endoscopic ... like Type 2 diabetes. The white paper ... in both GIE: Gastrointestinal Endoscopy, the peer-reviewed ...
... standards for teaching women and clinicians how to perform ... to detect lumps earlier and save lives. Widely-publicized ... of cancer. The Center for Disease Control reports that ... most common cancer among American females. The National ...
... keep blood vessels open to treat heart disease are ... the Journal of Interventional Cardiology . A case ... of the Detroit Medical Center Cardiovascular Institute, and her ... after the recently marketed Ion stent (Boston Scientific, Natick, ...
... of organic horticultural crops frequently fall below those of ... of organic production. Researchers recently studied the growth and ... with vermicompost and compared the results with plants grown ... area is needed to provide a base of information ...
... has found that people are willing to pay up to 29.91 ... Researchers surveyed the public in the two major urban centres ... were willing to pay in council tax or rent/mortgage payments for ... willing to pay more for greener spaces with greater tree coverage. ...
... poisonous snakes, a group of researchers at the University of ... small black, yellow and red serpent called the Texas coral ... insights into chronic and acute pain and provides new ... combat pain. The venom contains a toxic mixture of ...
Cached Medicine News:Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 3Health News:Public willing to pay more for greener urban spaces 2Health News:Public willing to pay more for greener urban spaces 3Health News:Snake spills venomous secrets 2Health News:Snake spills venomous secrets 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
Medicine Products: